Why Germany
Why Germany
The head of the nation’s top brain tumor clinic at Duke University has been working with a company in Germany for several years to connect patients with a new gene-based vaccine treatment. This vaccine treatment uses a patient's specific tumor mutations to create a vaccine which triggers his or her own immune system to kill cancer sneaky cells.
While this is not yet published, it is something whispered among doctors and researchers on Becky’s care team:
Dr. Saskia Biskup’s new gene-based vaccine treatment, which she first attempted in 2013, has been tried in 102 patients, 97 of whom are in remission or cancer free - and many of whom started with <6 months survival prognosis, including pancreatic, ovarian and brain cancer patients, among the worst types of cancer.
​
That’s a big number.
CeGat, Dr. Biskup’s company, has received CAP accreditation, which means that it not only is endorsed by American high standards but an international board.